Cardiotoxicity of mitozantrone assessed by stress and resting nuclear ventriculography.
Fourteen patients with advanced breast cancer were treated with a combination of vincristine, mitozantrone and prednisolone. Before, during and after cessation of treatment radionuclide assessment of ventricular performance was obtained at rest, in response to cold pressor-induced stress and on recovery from stress. Six of 14 patients (46%) developed abnormalities of left ventricular ejection fraction (LVEF). One patient developed clinical signs of cardiac failure. Mitozantrone is an active agent in the treatment of advanced breast cancer but it can produce cardiotoxicity. In this particular middle-aged population, changes in LVEF occurred over a wide range of cumulative doses. Further investigation is required to determine the nature and prognosis of this iatrogenic toxicity.
Cassidy
J
J
University Department of Clinical Oncology, Western General Hospital, Edinburgh, U.K.
Merrick
M V
MV
Smyth
J F
JF
Leonard
R C
RC
D000328:Adult; D000368:Aged; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000627:therapeutic use; D001943:Breast Neoplasms / Q000188:drug therapy*; D005260:Female; D006331:Heart Diseases / Q000139:chemically induced*; D006801:Humans; D008875:Middle Aged; D008942:Mitoxantrone / Q000009:adverse effects*; D011239:Prednisolone / Q000008:administration & dosage; D011897:Random Allocation; D013318:Stroke Volume / Q000187:drug effects; D014750:Vincristine / Q000008:administration & dosage
D014750:Vincristine; D011239:Prednisolone; D008942:Mitoxantrone